The Impact of Solitary and Multiple Positive Surgical Margins on Hard Clinical End Points in 1712 Adjuvant Treatment-Naive pT2-4 N0 Radical Prostatectomy Patients

被引:69
作者
Mauermann, Julian [1 ]
Fradet, Vincent [1 ]
Lacombe, Louis [1 ]
Dujardin, Thierry [1 ]
Tiguert, Rabi [1 ]
Tetu, Bernard [2 ]
Fradet, Yves [1 ]
机构
[1] Univ Laval, Ctr Hosp Univ Quebec, Dept Urol Surg, Quebec City, PQ, Canada
[2] Univ Laval, Ctr Hosp Univ Quebec, Dept Pathol, Quebec City, PQ, Canada
关键词
Biochemical recurrence; Metastases; Mortality; Positive surgical margins; Radical prostatectomy; Radiation therapy; ISUP CONSENSUS CONFERENCE; INTERNATIONAL-SOCIETY; SALVAGE RADIOTHERAPY; PROSTATIC-CARCINOMA; RADIATION-THERAPY; FOLLOW-UP; CANCER; SURVIVAL; TRIAL; MEN;
D O I
10.1016/j.eururo.2012.08.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Positive surgical margins (PSMs) increase the risk of biochemical recurrence (BCR) after radical prostatectomy (RP), but their impact on hard clinical end points is a topic of ongoing discussion. Objective: To evaluate the influence of solitary PSMs (sPSMs) and multiple PSMs (mPSMs) on important clinical end points. Design, setting, and participants: Data from 1712 patients from the Centre Hospitalier Universitaire de Quebec with pT2-4 N0 prostate cancer (PCa) and undetectable prostate-specific antigen after RP were analyzed. Intervention: RP without neoadjuvant or adjuvant treatment. Outcome measurements and statistical analysis: Kaplan-Meier analysis estimated survival functions, and Cox proportional hazards models addressed predictors of clinical end points. Results and limitations: Median follow-up was 74.9mo. A total of 1121 patients (65.5%) were margin-negative, 281 patients (16.4%) had sPSMs, and 310 patients (18.1%) had mPSMs. A total of 280 patients (16.4%) experienced BCR, and 197 patients (11.5%) were treated with salvage radiotherapy (SRT). Sixty-eight patients (4.0%) received definitive androgen deprivation therapy, 19 patients (1.1%) developed metastatic disease, and 15 patients (0.9%) had castration-resistant PCa (CRPC). Thirteen patients (0.8%) died from PCa, and 194 patients (11.3%) died from other causes. Ten-year Kaplan-Meier estimates for BCR-free survival were 82% for margin-negative patients, 72% for patients with sPSMs, and 59% for patients with mPSMs (p < 0.0001). Time to metastatic disease, CRPC, PCa-specific mortality (PCSM), or all-cause mortality did not differ significantly among the three groups (p = 0.991, p = 0.988, p = 0.889, and p = 0.218, respectively). On multivariable analysis, sPSMs and mPSMs were associated with BCR (hazard ratio [HR]: 1.711; p = 0.001 and HR: 2.075; p < 0.0001), but sPSMs and mPSMs could not predict metastatic disease (p = 0.705 and p = 0.242), CRPC(p = 0.705 and p = 0.224), PCSM (p = 0.972 and p = 0.260), or all-cause death (p = 0.102 and p = 0.067). The major limitation was the retrospective design. Conclusions: In a cohort of patients who received early SRT in 70% of cases upon BCR, sPSMs and mPSMs predicted BCR but not long-term clinical end points. Adjuvant radiotherapy for margin-positive patients might not be justified, as only a minority of patients progressed to end points other than BCR. PCSM was exceeded 15-fold by competing risk mortality. (C) 2012 Published by Elsevier B. V. on behalf of European Association of Urology.
引用
收藏
页码:19 / 25
页数:7
相关论文
共 29 条
  • [1] Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911)
    Bolla, M
    van Poppel, H
    Collette, L
    van Cangh, P
    Vekemans, K
    Da Pozzo, L
    de Reijke, TM
    Verbaeys, A
    Bosset, JF
    van Velthoven, R
    Maréchal, JM
    Scalliet, P
    Haustermans, K
    Piérart, M
    [J]. LANCET, 2005, 366 (9485) : 572 - 578
  • [2] The Impact of Positive Surgical Margins on Mortality Following Radical Prostatectomy During the Prostate Specific Antigen Era
    Boorjian, Stephen A.
    Karnes, R. Jeffrey
    Crispen, Paul L.
    Carlson, Rachel E.
    Rangel, Laureano J.
    Bergstralh, Eric J.
    Blute, Michael L.
    [J]. JOURNAL OF UROLOGY, 2010, 183 (03) : 1003 - 1009
  • [3] Biochemical Recurrence After Radical Prostatectomy: Multiplicative Interaction Between Surgical Margin Status and Pathological Stage
    Budaeus, Lars
    Isbarn, Hendrik
    Eichelberg, Christian
    Lughezzani, Giovanni
    Sun, Maxine
    Perrotte, Paul
    Chun, Felix K. H.
    Salomon, Georg
    Steuber, Thomas
    Koellermann, Jens
    Sauter, Guido
    Ahyai, Sascha A.
    Zacharias, Mario
    Fisch, Margit
    Schlomm, Thorsten
    Haese, Alexander
    Heinzer, Hans
    Huland, Hartwig
    Montorsi, Francesco
    Graefen, Markus
    Karakiewicz, Pierre I.
    [J]. JOURNAL OF UROLOGY, 2010, 184 (04) : 1341 - 1346
  • [4] Cao DF, 2011, UROLOGY, V77, P1409, DOI 10.1016/j.urology.2010.10.059
  • [5] Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials
    Collette, Laurence
    [J]. EUROPEAN UROLOGY, 2008, 53 (01) : 6 - 9
  • [6] Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
    Eggener, Scott E.
    Scardino, Peter T.
    Walsh, Patrick C.
    Han, Misop
    Partin, Alan W.
    Trock, Bruce J.
    Feng, Zhaoyong
    Wood, David P.
    Eastham, James A.
    Yossepowitch, Ofer
    Rabah, Danny M.
    Kattan, Michael W.
    Yu, Changhong
    Klein, Eric A.
    Stephenson, Andrew J.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (03) : 869 - 875
  • [7] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Epstein, JI
    Allsbrook, WC
    Amin, MB
    Egevad, LL
    Bastacky, S
    Beltrán, AL
    Berner, A
    Billis, A
    Boccon-Gibod, L
    Cheng, L
    Civantos, F
    Cohen, C
    Cohen, MB
    Datta, M
    Davis, C
    Delahunt, B
    Delprado, W
    Eble, JN
    Foster, CS
    Furusato, M
    Gaudin, PB
    Grignon, DJ
    Humphrey, PA
    Iczkowski, KA
    Jones, EC
    Lucia, S
    McCue, PA
    Nazeer, T
    Oliva, E
    Pan, CC
    Pizov, G
    Reuter, V
    Samaratunga, H
    Sebo, T
    Sesterhenn, I
    Shevchuk, M
    Srigley, JR
    Suzigan, S
    Takahashi, H
    Tamboli, P
    Tan, PH
    Têtu, B
    Tickoo, S
    Tomaszewski, JE
    Troncoso, P
    Tsuzuki, T
    True, LD
    van der Kwast, T
    Wheeler, TM
    Wojno, KJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
  • [8] Adjuvant radiotherapy for patients with locally advanced prostate cancer - A new standard?
    Ganswindt, Ute
    Stenzl, Arnulf
    Bamberg, Michael
    Belka, Claus
    [J]. EUROPEAN UROLOGY, 2008, 54 (03) : 528 - 542
  • [9] Prognostic impact of positive surgical margins in surgically treated prostate cancer:: Multi-institutional assessment of 5831 patients
    Karakiewicz, PI
    Eastham, JA
    Graefen, M
    Cagiannos, I
    Stricker, PD
    Klein, E
    Cangiano, T
    Schröder, FH
    Scardino, PT
    Kattan, MW
    [J]. UROLOGY, 2005, 66 (06) : 1245 - 1250
  • [10] EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
    Mottet, Nicolas
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    Mason, Malcolm
    Matveev, Vsevolod
    Schmid, Hans-Peter
    Van der Kwast, Theo
    Wiegel, Thomas
    Zattoni, Filiberto
    Heidenreich, Axel
    [J]. EUROPEAN UROLOGY, 2011, 59 (04) : 572 - 583